S&P TSX Capped Composite...

US Dollar vs CAD

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

PSTX Poseida Therapeutics Inc

2.47

0.00 (0.00%)

Pre Market

Last Updated: 03:00:28

Delayed by 15 minutes

Form EFFECT - Notice of Effectiveness

Poseida Therapeutics (NASDAQ:PSTX)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Poseida Therapeutics Charts.

Poseida Therapeutics (NASDAQ:PSTX)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Poseida Therapeutics Charts.

Poseida Therapeutics Inc News

Poseida Therapeutics to Present New Preclinical Data Supporting Non-Viral Gene Editing with P-KLKB1-101 for the Treatment of Hereditary Angioedema
Thursday 24 October 2024 (2 weeks ago) • PR Newswire (US)

Form SC 13G - Statement of Beneficial Ownership by Certain Investors
Tuesday 22 October 2024 (2 weeks ago) • Edgar (US Regulatory)

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche
Thursday 17 October 2024 (3 weeks ago) • PR Newswire (US)

MaxCyte Appoints Cynthia Collins to its Board of Directors
Tuesday 15 October 2024 (3 weeks ago) • GlobeNewswire Inc.

Poseida Therapeutics Named to Newsweek's List of the Top 200 America's Most Loved Workplaces for 2024
Thursday 3 October 2024 (1 month ago) • PR Newswire (US)

Form 8-K - Current report
Monday 30 September 2024 (1 month ago) • Edgar (US Regulatory)

Poseida Therapeutics Reports Positive Interim Phase 1 Results for Allogeneic CAR-T Therapy P-BCMA-ALLO1 with High Overall Response Rates in Heavily Pretreated Relapsed/Refractory Multiple Myeloma Patients
Friday 27 September 2024 (1 month ago) • PR Newswire (US)

Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
Monday 16 September 2024 (2 months ago) • PR Newswire (US)

Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual Meeting
Thursday 5 September 2024 (2 months ago) • PR Newswire (US)

Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple Myeloma
Wednesday 4 September 2024 (2 months ago) • PR Newswire (US)

Poseida Therapeutics to Present at Upcoming Investor Conferences
Thursday 29 August 2024 (2 months ago) • PR Newswire (US)

Form EFFECT - Notice of Effectiveness
Wednesday 14 August 2024 (3 months ago) • Edgar (US Regulatory)

More Poseida Therapeutics Inc News Articles

Bioelectronics (PK)

Northwest Biotherapeutics (QB)

Lightwave Logic

NioCorp Developments

Valiant Eagle (PK)

Anavex Life Sciences

Fannie Mae (QB)

GNCC Capital (CE)

Rennova Health (CE)

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions